Cite
HARVARD Citation
Tahir, H. et al. (n.d.). 258 Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial. Rheumatology. p. . [Online].